Victoria Johnson

Garetosmab-grts is the first treatment demonstrating reduced new heterotopic ossification lesions and flare-ups in adults with FOP.

Efgartigimod produced significant, sustained improvement in autoimmune myositis, including the first positive phase 3 results in IMNM.

Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.

Baricitinib achieved glucocorticoid-free remission in 65% of patients with new-onset polymyalgia rheumatica at week 16, versus 17% with placebo.

A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.

A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.

3-month topline data showed a 72% reduction in pain and a 109% improvement in function versus placebo, both exceeding prespecified FDA thresholds for Phase III advancement.

Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.

Findings from an independent, blinded re-adjudication of ADVOCATE's primary endpoints will be presented at an FDA hearing scheduled for July 2026.

Key changes in the 2026 ACR/SAA/SPARTAN guideline update elevate JAK inhibitors to a strong recommendation and introduce nociplastic pain guidance.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

Laura Coates, MBChB, PhD, discusses data showing early separation in ACR50 and disease activity measures at week 4, before substantial weight loss.

Check out what coverage RheumLive has slated for the upcoming congress in London.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

New JIA guidance urges early biologics, favors oral methotrexate, adds mental health screening, and reshapes tapering and monitoring.

Phase 2/3 China trial shows IL‑17A antibody vunakizumab rapidly improves radiographic axSpA symptoms vs placebo, with benefits lasting to 32 weeks.

The new approval is backed by ADAPT SERON results showing significant MG-ADL improvement and consistent safety.

April is Sjögren's Awareness Month and we took a look at how the field's fast-growing pipeline is reshaping care.

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

Experts discuss CTD-ILD guidance and nerandomilast reshape screening, progression monitoring, and multidisciplinary treatment.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

Take a look back at 5 RheumLive exclusive conversations ranging from PsA to giant cell arteritis from RWCS 2026 in Maui, Hawaii.

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.